- Molecular NameFamciclovir
- SynonymFamciclovirum [INN-Latin]; FCV
- Weight321.337
- Drugbank_IDDB00426
- ACS_NO104227-87-4
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.11
- pkaN/A
- LogD (pH=7, predicted)1.11
- Solubility (experiment)22.7 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.37
- LogSw (predicted, AB/LogsW2.0)9.4
- Sw (mg/ml) (predicted, ACD/Labs)0.14
- No.of HBond Donors2
- No.of HBond Acceptors9
- No.of Rotatable Bonds9
- TPSA122.22
- StatusFDA approved
- AdministrationN/A
- PharmacologyA guanine analogue antiviral drug used for the treatment of various herpesvirus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability.
- Absorption_value77.0
- Absorption (description)Famciclovir is rapidly absorbed after oral administration
- Caco_2N/A
- Bioavailability77.0
- Protein binding20.0
- Volume of distribution (VD)0.98 to 1.08 L/kg
- Blood/Plasma Partitioning ratio (D_blood)The blood:plasma ratio for the metabolite, penciclovir is approx. 1.0.
- MetabollsmConverted, by deacetylation, in blood, and oxidation (aldehyde oxidase), in the liver, to penciclovir (BR-39123) and several inactive metabolites. Virtually no famciclovir is detected in plasma or urine. Penciclovir is converted by intracellular virus-induced thymine kinase to penciclovir triphosphate which is responsible for the antiviral activity.
- Half life2~3 h
- ExcretionThe drug is excreted, primarily, in urine as the metabolite, penciclovir, and the 6-deoxy precursor, BRL-42359. 73% of penciclovir can be detected in urine over 24 h and the remainder appears in faeces. Elimination is reduced in patients with renal impairment.
- Urinary ExcretionN/A
- Clerance0.48 L/h/kg
- ToxicitySymptoms of overdose include constipation, diarrhea, dizziness, fatigue, fever, headache, nausea, and vomiting.
- LD50 (rat)N/A
- LD50 (mouse)N/A